Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AGEN |
---|---|---|
09:32 ET | 35487 | 5.27 |
09:34 ET | 26127 | 5.5792 |
09:36 ET | 27025 | 5.6 |
09:38 ET | 7585 | 5.53 |
09:39 ET | 7419 | 5.56 |
09:41 ET | 7144 | 5.65 |
09:43 ET | 3830 | 5.6312 |
09:45 ET | 4626 | 5.625 |
09:48 ET | 18013 | 5.7 |
09:50 ET | 9667 | 5.85 |
09:52 ET | 8138 | 5.84 |
09:54 ET | 7811 | 5.95 |
09:56 ET | 23291 | 5.9902 |
09:57 ET | 21279 | 6.05 |
09:59 ET | 11637 | 6.0184 |
10:01 ET | 13731 | 5.8704 |
10:03 ET | 5853 | 5.8 |
10:06 ET | 7839 | 5.79 |
10:08 ET | 2248 | 5.79 |
10:10 ET | 17574 | 5.78 |
10:12 ET | 1967 | 5.76 |
10:14 ET | 6102 | 5.8 |
10:15 ET | 5141 | 5.735 |
10:17 ET | 5517 | 5.69 |
10:19 ET | 682 | 5.7 |
10:21 ET | 3587 | 5.6591 |
10:24 ET | 4099 | 5.58 |
10:26 ET | 3045 | 5.55 |
10:28 ET | 21196 | 5.53 |
10:30 ET | 1303 | 5.4999 |
10:32 ET | 14232 | 5.3701 |
10:33 ET | 11321 | 5.32 |
10:35 ET | 12986 | 5.35 |
10:37 ET | 36572 | 5.265 |
10:39 ET | 10964 | 5.22 |
10:42 ET | 11115 | 5.23 |
10:44 ET | 990 | 5.235 |
10:46 ET | 10957 | 5.22 |
10:48 ET | 1238 | 5.1806 |
10:50 ET | 4004 | 5.195 |
10:51 ET | 3600 | 5.22 |
10:53 ET | 2173 | 5.208 |
10:55 ET | 450 | 5.2099 |
10:57 ET | 2529 | 5.215 |
11:00 ET | 1793 | 5.215 |
11:02 ET | 1500 | 5.215 |
11:04 ET | 1000 | 5.215 |
11:06 ET | 3999 | 5.18 |
11:08 ET | 14678 | 5.175 |
11:09 ET | 200 | 5.155 |
11:11 ET | 800 | 5.16 |
11:13 ET | 2609 | 5.2 |
11:15 ET | 7990 | 5.2 |
11:18 ET | 19036 | 5.37 |
11:20 ET | 3231 | 5.33 |
11:22 ET | 4001 | 5.4 |
11:24 ET | 3601 | 5.3899 |
11:26 ET | 1600 | 5.4199 |
11:27 ET | 100 | 5.41 |
11:29 ET | 1791 | 5.4 |
11:31 ET | 556 | 5.35 |
11:33 ET | 3743 | 5.3 |
11:36 ET | 6400 | 5.33 |
11:38 ET | 5152 | 5.375 |
11:40 ET | 3816 | 5.34 |
11:42 ET | 500 | 5.32 |
11:44 ET | 1700 | 5.31 |
11:47 ET | 3492 | 5.31 |
11:49 ET | 2554 | 5.31 |
11:51 ET | 29421 | 5.27 |
11:54 ET | 82879 | 5.145 |
11:56 ET | 2120 | 5.1601 |
11:58 ET | 1153 | 5.18 |
12:00 ET | 6926 | 5.145 |
12:02 ET | 14014 | 5.125 |
12:03 ET | 11456 | 5.078 |
12:05 ET | 13823 | 5.035 |
12:07 ET | 23949 | 5.07 |
12:09 ET | 14804 | 5.01 |
12:12 ET | 4543 | 5.03 |
12:14 ET | 17166 | 4.95 |
12:16 ET | 9609 | 4.9851 |
12:18 ET | 8617 | 4.91 |
12:20 ET | 10773 | 4.8829 |
12:21 ET | 5682 | 4.9497 |
12:23 ET | 27251 | 4.94 |
12:25 ET | 6666 | 4.945 |
12:27 ET | 16377 | 4.915 |
12:30 ET | 9110 | 4.91 |
12:32 ET | 23463 | 4.895 |
12:34 ET | 6288 | 4.9 |
12:36 ET | 3068 | 4.926 |
12:38 ET | 1300 | 4.94 |
12:39 ET | 795 | 4.94 |
12:41 ET | 500 | 4.945 |
12:43 ET | 8441 | 4.96 |
12:45 ET | 500 | 4.965 |
12:48 ET | 15922 | 4.98 |
12:50 ET | 5765 | 4.9769 |
12:52 ET | 7360 | 4.9783 |
12:54 ET | 4701 | 4.92 |
12:56 ET | 1103 | 4.91 |
12:57 ET | 4307 | 4.9 |
12:59 ET | 26186 | 4.86 |
01:01 ET | 12482 | 4.86 |
01:03 ET | 1645 | 4.84 |
01:06 ET | 1431 | 4.84 |
01:08 ET | 5400 | 4.81 |
01:10 ET | 1467 | 4.815 |
01:12 ET | 2114 | 4.82 |
01:14 ET | 8971 | 4.81 |
01:15 ET | 3278 | 4.855 |
01:17 ET | 5500 | 4.83 |
01:19 ET | 100 | 4.8499 |
01:21 ET | 3677 | 4.865 |
01:24 ET | 1565 | 4.81 |
01:26 ET | 6637 | 4.8 |
01:28 ET | 739 | 4.8 |
01:30 ET | 6589 | 4.82 |
01:32 ET | 8935 | 4.835 |
01:33 ET | 4272 | 4.86 |
01:35 ET | 4322 | 4.8465 |
01:37 ET | 1200 | 4.85 |
01:39 ET | 4220 | 4.885 |
01:42 ET | 6781 | 4.92 |
01:44 ET | 6214 | 4.925 |
01:46 ET | 1004 | 4.93 |
01:48 ET | 1100 | 4.93 |
01:50 ET | 9227 | 4.97 |
01:51 ET | 3793 | 4.98 |
01:53 ET | 3166 | 4.975 |
01:55 ET | 3908 | 4.99 |
01:57 ET | 1774 | 4.935 |
02:00 ET | 2125 | 4.93 |
02:02 ET | 1396 | 4.915 |
02:04 ET | 2179 | 4.92 |
02:06 ET | 2300 | 4.9366 |
02:08 ET | 6379 | 4.94 |
02:09 ET | 1600 | 4.94 |
02:11 ET | 5326 | 5.02 |
02:13 ET | 4842 | 5.04 |
02:15 ET | 3954 | 5.03 |
02:18 ET | 6675 | 5.06 |
02:20 ET | 6105 | 5.03 |
02:22 ET | 1400 | 5.03 |
02:24 ET | 2300 | 5.04 |
02:26 ET | 700 | 5.06 |
02:27 ET | 1112 | 5.06 |
02:29 ET | 3753 | 5.065 |
02:31 ET | 2348 | 5.08 |
02:33 ET | 900 | 5.08 |
02:36 ET | 726 | 5.08 |
02:38 ET | 800 | 5.08 |
02:40 ET | 400 | 5.08 |
02:42 ET | 4676 | 5.07 |
02:44 ET | 8117 | 5.0579 |
02:47 ET | 803 | 5.06 |
02:49 ET | 1541 | 5.06 |
02:51 ET | 4046 | 5.03 |
02:54 ET | 3165 | 5.02 |
02:56 ET | 17653 | 5.02 |
02:58 ET | 1648 | 4.97 |
03:00 ET | 1740 | 4.98 |
03:02 ET | 1224 | 5.005 |
03:03 ET | 1981 | 5.005 |
03:05 ET | 3007 | 5.0599 |
03:07 ET | 2713 | 5.05 |
03:09 ET | 2315 | 5.05 |
03:12 ET | 2193 | 5.045 |
03:14 ET | 4928 | 5.0734 |
03:16 ET | 515 | 5.08 |
03:18 ET | 5316 | 5.08 |
03:20 ET | 935 | 5.065 |
03:21 ET | 1706 | 5.08 |
03:23 ET | 1950 | 5.05 |
03:25 ET | 2176 | 5.04 |
03:27 ET | 1773 | 5.035 |
03:30 ET | 1235 | 5.025 |
03:32 ET | 12509 | 4.98 |
03:34 ET | 10863 | 4.95 |
03:36 ET | 6179 | 4.945 |
03:38 ET | 5804 | 4.92 |
03:39 ET | 3265 | 4.945 |
03:41 ET | 1922 | 4.945 |
03:43 ET | 6967 | 4.9071 |
03:45 ET | 8942 | 4.955 |
03:48 ET | 4929 | 4.9401 |
03:50 ET | 45052 | 5 |
03:52 ET | 3784 | 4.965 |
03:54 ET | 4712 | 4.965 |
03:56 ET | 17866 | 4.95 |
03:57 ET | 9562 | 4.955 |
03:59 ET | 23053 | 4.97 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Agenus Inc | 113.1M | -7.1x | --- |
FibroGen Inc | 125.4M | -0.4x | --- |
Karyopharm Therapeutics Inc | 160.7M | -1.0x | --- |
Sangamo Therapeutics Inc | 104.7M | -0.3x | --- |
Sutro Biopharma Inc | 286.9M | -2.1x | --- |
Seres Therapeutics Inc | 94.7M | -0.7x | --- |
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $113.1M |
---|---|
Revenue (TTM) | $156.3M |
Shares Outstanding | 20.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.43 |
EPS | $-0.70 |
Book Value | $-0.41 |
P/E Ratio | -7.1x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -102.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.